These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 1430092)

  • 1. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.
    Massa G; Bouillon R; Vanderschueren-Lodeweyckx M
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1298-302. PubMed ID: 1430092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
    Saggese G; Federico G; Cinquanta L
    Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
    Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of short term treatment with growth hormone and ethinyl estradiol on lower leg growth rate in girls with Turner's syndrome.
    Ross JL; Cassorla F; Carpenter G; Long LM; Royster MS; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Sep; 67(3):515-8. PubMed ID: 3410937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
    Massa G; Maes M; Heinrichs C; Vandeweghe M; Craen M; Vanderschueren-Lodeweyckx M
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
    Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. (Dutch Working Group on Growth Hormone).
    van Teunenbroek A; de Muinck Keizer-Schrama S; Stijnen T; Waelkens J; Wit JM; Vulsma T; Gerver WJ; Reeser H; Delemarre-van de Waal H; Jansen M; Drop S
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):451-9. PubMed ID: 9196608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
    Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
    J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific, time-dependent actions of low-dose ethinyl estradiol administration on the episodic release of growth hormone, follicle-stimulating hormone, and luteinizing hormone in prepubertal girls with Turner's syndrome.
    Mauras N; Rogol AD; Veldhuis JD
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1053-8. PubMed ID: 2507569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Delemarre-van de Waal HA; Vulsma T; Wit JM; Rouwé CW; Reeser HM; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation.
    Zadik Z; Landau H; Chen M; Altman Y; Lieberman E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):412-6. PubMed ID: 1386373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ; Ho KK; Lazarus L
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
    Nilsson KO; Albertsson-Wikland K; Alm J; Aronson S; Gustafsson J; Hagenäs L; Häger A; Ivarsson SA; Karlberg J; Kriström B; Marcus C; Moell C; Ritzen M; Tuvemo T; Wattsgård C; Westgren U; Westphal O; Aman J
    J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
    Vanderschueren-Lodeweyckx M; Massa G; Maes M; Craen M; van Vliet G; Heinrichs C; Malvaux P
    J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome.
    Kamp GA; Kuilboer MM; Wynne HJ; Rongen-Westerlaken C; Johnson ML; Veldhuis JD; Wit JM
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1604-9. PubMed ID: 8501169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acute high dose and chronic low dose estrogen on plasma somatomedin-C and growth in patients with Turner's syndrome.
    Copeland KC
    J Clin Endocrinol Metab; 1988 Jun; 66(6):1278-82. PubMed ID: 3372687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I.
    Foster CM; Borondy M; Markovs ME; Hopwood NJ; Kletter GB; Beitins IZ
    Pediatr Res; 1994 Feb; 35(2):218-22. PubMed ID: 7513079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.